Coronary heart disease
Conditions
Interventions
Salvia polyphenolate group:Intravenous infusion of salvianolate polyphenolate
Placebo group:0.9% N.S.
Sponsors
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) There are symptoms of angina or angina; (2) Coronary angiography showed a stenosis degree of 50%-70%, Fractional Flow Reserve (FFR)>0.8, and a microcirculation resistance index (IMR)>25; (3) The patient did not receive Danshen polyphenolate before surgery.
Exclusion criteria
Exclusion criteria: (1) Patients with left main lesions; (2) Patients with severe cardiac insufficiency (New York Heart Association grade III and above), severe renal insufficiency (eGFR 3×ULN), and patients with asthma history; (3) complicated with severe cerebrovascular disease; patients with co-infection, hematopoietic dysfunction, tumor and mental illness; (4) those with malignant arrhythmia or III° atrioventricular block; (5) taking other Chinese medicines for treating angina at the same time; (6) pregnant or lactating women; (7) Those who are participating in other clinical trials within the past month or currently; (8) Those who are allergic to the known ingredients of this medicine; (9) Other circumstances that the investigator believes are not suitable for inclusion, or the patient or family member does not agree with the treatment plan of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Index of Microcirculatory resistance; | — |
Countries
China
Contacts
Public ContactWenbin Zhang
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Outcome results
None listed